LMP-1 antisense oligodeoxynucleotide treatment suppresses LMP-1 protein levels. Western blot analysis of LMP-1 and EBNA-1 protein expression in 2 EBV-positive lymphoblastoid cell lines, 11-23 and X50-7, was performed after exposure to unmodified antisense oligodeoxynucleotide targeted to LMP-1 (codons 1 through 5) for 48 hours. Lane 1, untreated control; lane 2, LMP-1 antisense-treated (50 μmol/L); lane 3, LMP-1 antisense-treated (5 μmol/L); lane 4, control oligodeoxynucleotide (SS1)-treated (50 μmol/L). Duplicate sets of samples for each condition were immunoblotted for LMP-1 or EBNA-1, as described in the Methods.